This hypothesis is supported by a previous study showing that blockade of gp91phox, a subunit of NADPH oxidase, attenuates Ang II infusion-associated-hypertension and cardiac hypertrophy (Bendall et al., 2002). This evidence concerns the gene FMO5 and cardiac hypertrophy.